Full automation of spinal stereotactic radiosurgery and stereotactic body radiation therapy treatment planning using Varian Eclipse scripting

Jose R. Teruel | Martha Malin | Elisa K. Liu | Allison McCarthy | Kenneth Hu | Benjamin T. Cooper | Erik P. Sulman | Joshua S. Silverman | David Barbee

Department of Radiation Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA

Author to whom correspondence should be addressed. Jose R. Teruel
E-mail: jose.teruel@nyulangone.org; Telephone: 212-731-6166.

Funding information
NYU Langone Health

Abstract
The purpose of this feasibility study is to develop a fully automated procedure capable of generating treatment plans with multiple fractionation schemes to improve speed, robustness, and standardization of plan quality. A fully automated script was implemented for spinal stereotactic radiosurgery/stereotactic body radiation therapy (SRS/SBRT) plan generation using Eclipse v15.6 API. The script interface allows multiple dose/fractionation plan requests, planning target volume (PTV) expansions, as well as information regarding distance/overlap between spinal cord and targets to drive decision-making. For each requested plan, the script creates the course, plans, field arrangements, and automatically optimizes and calculates dose. The script was retrospectively applied to ten computed tomography (CT) scans of previous cervical, thoracic, and lumbar spine SBRT patients. Three plans were generated for each patient — simultaneous integrated boost (SIB) 1800/1600 cGy to gross tumor volume (GTV)/PTV in one fraction; SIB 2700/2100 cGy to GTV/PTV in three fractions; and 3000 cGy to PTV in five fractions. Plan complexity and deliverability patient-specific quality assurance (QA) was performed using ArcCHECK with an Exradin A16 chamber inserted. Dose objectives were met for all organs at risk (OARs) for each treatment plan. Median target coverage was GTV V100% = 87.3%, clinical target volume (CTV) V100% = 95.7% and PTV V100% = 88.0% for single fraction plans; GTV V100% = 95.6, CTV V100% = 99.6% and PTV V100% = 97.2% for three fraction plans; and GTV V100% = 99.6%, CTV V100% = 99.1% and PTV V100% = 97.2% for five fraction plans. All plans (n = 30) passed patient-specific QA (>90%) at 2%/2 mm global gamma. A16 chamber dose measured at isocenter agreed with planned dose within 3% for all cases. Automatic planning for spine SRS/SBRT through scripting increases efficiency, standardizes plan quality and approach, and provides a tool for target coverage comparison of different fractionation schemes without the need for additional resources.
1 | INTRODUCTION

Spinal metastases are devastating complications of malignant tumors that can decrease quality of life due to pain, impaired mobility, or neurologic disturbances.\(^1,2\) Surgical resection has been the mainstay of treatment to reduce tumor burden and stabilize the surrounding anatomy, but may not be feasible in patients with poor performance status or tumors that abut critical organs.\(^3\) Radiation, now widely adopted for the treatment of spinal metastases, can be delivered as adjuvant to surgery, or as definitive treatment, to improve tumor and symptomatic control. The adoption of stereotactic immobilization and real-time image guidance along with advances in treatment planning has allowed for treatment of spinal lesions using larger fraction sizes to improve tumor control and reduce treatment burden.\(^4\)

RTOG 0631 phase II concluded that spine SRS was safe and feasible to be implemented in a high-level cooperative group trial.\(^5\) Single institution studies demonstrate an advantage of using SRS/ SBRT in terms of increased local control and complete response compared to conventional three-dimensional conformal radiotherapy (3DCRT).\(^6-13\) Sprave et al.\(^14\) reported improved pain response on a randomized phase II trial evaluating single fraction spine SBRT vs 3DCRT. The SABR-COMET randomized phase II trial compared standard 3DCRT palliative radiotherapy to SBRT for oligometastatic patients (including patients with spinal metastases) and reported a median overall survival of 28 months in the control group vs 41 months in the SABR group. Treatment-related deaths occurred in 3 (none of which were spine) of 66 patients after SABR, compared to none (n = 33) in the control group.\(^12\) The most feared complication from spine SRS is radiation myelopathy. Therefore, the dose to the spinal cord when performing spine SRS needs to be tightly controlled. A retrospective review on 1388 patients reported a 0.4% rate of myelopathy,\(^16\) and prospective studies have presented a range between 0 and 3%.\(^5,17-19\) Other relevant toxicities associated with spine SRS treatments are vertebral compression fractures (VCF)\(^20-22\) and esophageal toxicity (fistula, ulcer, stenosis).\(^23,24\)

Current approaches to spine SRS/SBRT require generation of complex treatment plans using intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) treatment delivery techniques. Spine SRS/SBRT targets are often adjacent to the spinal cord and esophagus, both organs at risk (OARs) where overdose can lead to unacceptable complications such as myelopathy and esophageal perforation.\(^25,26\) In order to achieve adequate dose coverage on the target while limiting the dose to OARs, spine SRS treatment plans must have steep dose gradients. Additionally, the high dose region must often have a concave shape to align to the spinal canal/vertebral body interface. The resulting treatment plans are often highly modulated and can push the limits of the accuracy of the treatment planning system. One study found that almost 15% of treatment plans were unfit for clinical use as they failed patient-specific quality assurance (QA).\(^27\)

Various studies have explored ways to improve the planning techniques used in spine SRS/SBRT planning.\(^27-29\) Multiple groups have compared IMRT and VMAT planning approaches with the typical finding that VMAT-based plans improved PTV coverage over IMRT approaches.\(^28-30\) Several studies have evaluated specific technical factors in the planning process. Snyder et al.\(^28\) evaluated the use of jaw tracking and the impact of different energies on dosimetric metrics. Ayala et al.\(^27\) found that plan quality could be retained, treatment efficiency increased, and IMRT QA pass rates improved by limiting the number of segments per beam and increasing the minimum area per segment for step-and-shoot spine SRS plans. Different planning and treatment delivery systems used for spine SRS were compared by Moustakis et al.\(^30\) Finally, Saenz et al. evaluated a spine-specific treatment planning system with a new optimization algorithm developed to overcome some of the limits found in traditional multipurpose planning systems.\(^31\)

The optimal dose and fractionation scheme for spine SRS/SBRT is debated with widely varying approaches in clinical practice.\(^32\) If planning goals for one fractionation scheme cannot be adequately met, one approach is to change the fractionation to improve tumor coverage. This patient-specific exploratory treatment planning to evaluate multiple fractionation schemes is time consuming and often clinically unfeasible in the setting of manually generated treatment plans. As the burden of spinal metastases increases secondary to the longer life expectancy of cancer patients, there is a growing need for efficient and accurate treatment planning in spine SRS.

Automated and semiautomated treatment planning approaches have the potential to produce high-quality clinical plans while reducing the time spent on treatment optimization, allowing for unsupervised optimization and calculation, therefore decreasing the planning time. Exploratory demonstrations in head and neck,\(^33\) breast,\(^34,35\) and other sites\(^36-38\) have produced results comparable to corresponding clinical plans. However, most studies focused on optimization approaches alone, which does not account for the complete treatment planning process. In addition, the translation of those results to the spine is challenging. An application of knowledge-based planning has been explored for spine tumors, but cannot be used to evaluate multiple fractionation schemes.\(^39\) There remains a critical need to generate multiple high-quality plans for different fractionation schemes in a clinically feasible manner.

The purpose of this feasibility study is to develop a fully automated procedure, using a widely available, all-purpose treatment planning software capable of generating treatment plans with multiple fractionation schemes to improve speed, robustness, and
standardization of plan quality. Using only a limited number of user inputs, automated treatment plans can be generated to aid in clinical decision-making and to decrease the required treatment planning time.

2 MATERIALS AND METHODS

2.A Subjects

Ten previously treated spine SBRT patients from our institution were anonymized and retrospectively replanned using the automatic treatment planning script. The patient dataset included targets treating the cervical (2), thoracic (7), and lumbar (1) spine regions. CT simulation was performed on a Siemens SOMATOM scanner (Siemens, Erlangen, Germany) with the following scan protocol: 1.5 mm slice thickness, 500 mm acquisition diameter, and extended field of view (FOV) reconstruction of 650 mm. The use of anonymized retrospective CT scans for dosimetry studies was approved by our Internal Review Board (IRB S18-00659).

2.B Treatment planning script

A fully automated script for spine SRS/SBRT plan generation, optimization, and calculation was developed using the Eclipse scripting application programming interface (ESAPI) v15.6 (Varian Medical Systems, Palo Alto, CA). The script was written in C# using the Visual Studio environment (Microsoft, Redmond, WA), Windows presentation foundation (WPF), and the Eclipse API binary libraries provided with Eclipse v15.6. The autoplan generation script requires completed structure delineation, including all organs at risk (OARs), plus the gross tumor volume (GTV), and clinical target volume (CTV). Gross tumor volume and CTV were contoured following consensus guidelines for spine SRS. For all these cases, the spinal cord was contoured using either magnetic resonance imaging (MRI), CT myelogram, or both. Initial script execution presents a graphic user interface (GUI) displaying treatment options and information (Fig. 1). The script GUI allows the user to select a prescription template (radiosensitive or radioresistant), and three options for PTV generation: (a) PTV = CTV; (b) PTV = CTV plus a 1-mm isotropic margin; (c) PTV = CTV plus a 2-mm isotropic margin. Information regarding distance or overlap between spinal cord and targets is provided to assist with clinical decision-making. This metric is presented using two approaches: Shortest distance between spinal cord and GTV/PTV, and shortest distance between spinal cord and GTV/PTV centroid. Finally, for the prescription, template selected the script offers the user the option to select three different fractionations and proceed with the execution.

For each requested plan, the script creates the course, plans, beam arrangement, optimization structures, digitally reconstructed radiographs (DDRs), and automatically optimizes and calculates dose. Optimization structures included high-resolution structures forcing the dose fall-off between targets and the most proximal organs at risk, such as the spinal cord and the esophagus, to ensure that there are no conflicting objectives. Additional optimization structures included rings for dose fall-off control and structures to define dose decrease between SIB dose level and the lower dose target region that should receive complete coverage. Priority is given to meet the maximum dose constraint to spinal cord and esophagus. The script loads the required optimization objectives based on the structures present in the structure set, including the following structures (if present): GTV, CTV, PTV, spinal cord, cauda equina, esophagus, brachial plexus, heart, trachea, skin, small bowel, stomach, colon, rectum, kidneys, lungs, and sacral plexus. At a minimum GTV, CTV and spinal cord (and/or cauda equina if lumbar spine) have to be present for the script to run. If any of these structures are not contoured, an error is launched that alerts the user. The PTV is automatically contoured by the criteria selected by the user in the GUI as specified in the preceding section. Additionally, planning organ at risk volumes (PRVs) for spinal cord and cauda equina are created using a 2-mm expansion.

Finally, the script generates dose verification plans for SNC ArcCHECK (Sun Nuclear, Melbourne, FL), exports the plan to Mobius (Varian) and RadCalc (Lifeline, Austin, TX) for monitor units (MUs) check, and creates a dose objectives summary document for each plan.

2.C Treatment plans

For this study, three plans were automatically generated for each patient according to our radiosensitive de novo prescription scheme that included the following: (a) simultaneous integrated boost (SIB) plan with 1800 cGy/1600 cGy dose to GTV/PTV in one fraction; (b) SIB 2700 cGy/2100 cGy dose to GTV/PTV in three fractions; (c) 3000 cGy dose to PTV in five fractions. The use of SIB for single or three fractions treatments has been reported previously and used for this retrospective feasibility study. Dose objectives for each fractionation are reported in Tables 1 and 2 and are based on previous evidence to minimize rate of toxicities. All treatment plans were calculated for delivery on a Varian Edge treatment machine equipped with high-resolution multileaf collimator (HD120 MLC). All plans used the same field arrangement of four co-planar full arcs with the isocenter automatically located at the GTV centroid and four different collimation rotations: 4°, 356°, 7°, 353°. Additional settings include the use of 10X flattening filter-free (FFF) energy, analytic anisotropic algorithm (AAA), photon optimizer (PO) and a 0.125-cm calculation resolution. Optimization convergence mode was set to “on” for all cases. Intermediate dose calculation and normal tissue objective were employed for optimization.

2.D Patient-specific QA

To evaluate deliverability of the treatment plans, patient-specific QA was performed for all 30 individual plans (ten treatment plans for each fractionation scheme). Dose verification plans were created for a SNC ArcCHECK diode array device and evaluation was carried out using the composite plan. Global gamma metric passing rates were
evaluated using three different threshold levels — 3% at 2 mm, 2% at 2 mm, and 3% at 1 mm, all with a 10% threshold dose.

2.E | Ion chamber measurement

For each patient-specific QA measurement, the dose to the center of the ArcCHECK was measured with an Exradin A16 micro ion chamber (Standard Imaging, Middleton, WI) that was inserted in the ArcCheck using the appropriate acrylic holder. The deviation between the dose in the Eclipse treatment plan (TP) and the dose delivered to the ion chamber (IC) was calculated as:

\[
\text{Dose deviation} (\%) = 100 \times \frac{\text{Dose}_{IC} - \text{Dose}_{TP}}{\text{Dose}_{TP}}
\]

To convert the charge reading to dose, the average of five 100 MU open field measurements (10 × 10 cm) with the ion chamber at isocenter inserted in the ArcCHECK was referenced to the dose reported in Eclipse for the same open beam setting.

3 | RESULTS

The location of the spinal tumors used in this study encompassed the cervical, thoracic, and lumbar spine. Lesions were located in C6, C6/C7 (continuous GTV contour), T2/T4 (individual GTV contours and combined CTV), T6, T7, T9, T10, T11, and L3. The median GTV, CTV, and PTV volumes were 5.3, 30.3, and 50.3 cm³, ranging between 0.8 and 43.7 cm³, between 9.6 and 54.6 cm³, and between 18.2 and 82.8 cm³ respectively. The majority of the automated tasks (plan creation, beam setup, optimization structure creation, and optimization template loading) were completed in <5 s. Using the settings indicated in the methods, a complete run from start to finish including the generation of three treatment plans with different fractionation was completed in under 2 h, with each plan taking approximately 30–40 min.

Single fraction and three fraction plans for one cervical, one thoracic, and one lumbar case are presented side by side in Fig. 2. Dose objectives and results for single fraction and three fraction plans including targets and OARs are summarized in Table 1. A summary of dosimetric results for five fraction plans including targets, spinal cord, and cauda equina are presented in Table 2. Dose objectives were met for all OARs for each treatment plan including the three possible fractionations. The highest level of target coverage was obtained for five fraction plans. Three fraction plans met all target coverage constraints in all scenarios with the exception of the GTV due to the high dose required in the SIB prescription schema. As expected, single fraction plans produced the biggest compromise in target coverage due to the largest difference between the dose that the OARs were allowed to receive, particularly the spinal cord, and the prescription dose to the targets.

The dose volume histograms for one case and the three different fractionations are presented in Fig. 3. The median PTV Conformity Index using the 100% isodose line (CI 100%) was 1.16 for single fraction plans, 1.20 for three fraction plans, and 1.18 for five fraction plans. For one of the cases only, PTV CI 100% was 1.4 or higher (1.40 for the three fraction plan and 1.42 for the five fraction plan). Among the three fractionations, single fraction plans had the lowest amount of MUs per cGy. Median number of MUs/cGy was 2.91, 3.29, and 3.56 for single fraction, three fractions, and five fractions plan respectively. The ranges and total number of MUs is...
Median values with range (minimum, maximum) in parentheses.

**TABLE 1** Dose objectives and results for single fraction and three fraction plans generated automatically for ten cases.

| Structure | Dose objective (1fx) | Result (1fx) | Dose objective (3fx) | Result (3fx) |
|-----------|---------------------|-------------|---------------------|-------------|
| GTV (n = 10) | V100% ≥ 95% | 87.3% (76.2%, 97.2%) | V100% ≥ 95% | 95.6% (89.1%, 99.3%) |
| CTV (n = 10) | Dmax < 130% | 122.3% (114.1%, 130.3%) | Dmax < 130% | 124.8% (111.0%, 130.2%) |
| PTV (n = 10) | V100% ≥ 90-80% | 95.7% (79.7%, 100%) | V100% ≥ 90-80% | 99.6% (97.9%, 100.0%) |
| Spinal Cord (n = 9) | D0.035cc < 1200cGy | 1079.9 (938.0, 1177.4) cGy | D0.035cc < 2390cGy | 1846.2 (1603.3, 2080.5) cGy |
| Spinal Cord + 2mm (n = 9) | D0.035cc < 1200cGy | 328.0 (0.0, 0.992) cc | D0.035cc < 2390cGy | 451.0 (197.9, 936) cc |
| Skin (n = 8) | V100cc < 1.2cc | 1294.4 (549.3, 1619.3) cGy | D0.035cc < 2500cGy | 1737.8 (646.2, 2277.0) cGy |
| Heart (n = 5) | V100cc < 1.2cc | 0.249 (0.0, 0.712) cc | D0.035cc < 3000cGy | 923.6 (276.8, 1831.6) cGy |
| Lungs (n = 6) | V100cc < 1.2cc | 0.0 (0.0, 0.0) cc | D0.035cc < 3000cGy | 0.0 (0.0, 0.0) cc |
| Liver (n = 4) | V100cc < 1.2cc | 0.0 (0.0, 0.0) cc | D0.035cc < 3000cGy | 985.3 (684.4, 1391.8) cGy |
| V100cc < 1.2cc | 0.0 (0.0, 0.0) cc | 2207.0 (1886.4, 3282.2) cc | MVS1160ccGy > 1500cc | 2262.7 (1895.0, 3238.0) cc |
| Trachea (n = 3) | V100cc < 1.2cc | 0.892 (0.012, 3.202) cc | V100cc < 1.2cc | 0.005 (0.0, 1.932) cc |
| Brachial Plexus, Right (n = 2) | V100cc < 1.2cc | 1547.1 (1546.2, 1548.0) cGy | D0.035cc < 2400cGy | 2211.6 (2198.5, 2224.7) cGy |
| Cauda Equina (n = 1) | V100cc < 1.2cc | 0.205 (0.059, 0.350) cc | V100cc < 1.2cc | 0.138 (0.041, 0.235) cc |
| Cauda Equina + 2mm (n = 1) | V100cc < 1.2cc | 1177.8 cGy | D0.035cc < 2400cGy | 2050.9 cGy |
| Cauda Equina + 2mm (n = 1) | V100cc < 1.2cc | 0.009 cc | V100cc < 1.2cc | 0.0 cc |
| Cauda Equina + 2mm (n = 1) | V100cc < 1.2cc | 1424.6 cGy | D0.035cc < 2600cGy | 2409.1 cGy |
| Median values with range (minimum, maximum) in parentheses.

**TABLE 2** Dose objectives and results for five fraction plans generated automatically for ten cases.

| Structure | Dose objective | Result |
|-----------|---------------|--------|
| GTV (n = 10) | V100% ≥ 95% | 99.6% (96.1%, 100%) |
| CTV (n = 10) | V100% ≥ 90-80% | 99.1% (96.7%, 100%) |
| PTV (n = 10) | Dmax < 130% | 128.6% (110.5%, 130.0%) |
| Spinal Cord (n = 9) | D0.035cc < 3000cGy | 2423.6 (1711.0, 2691.3) cGy |
| Spinal Cord + 2mm (n = 9) | D0.035cc < 3000cGy | 2847.7 (2554.5, 2878.1) cGy |
| Cauda Equina (n = 1) | D0.035cc < 3200cGy | 2886.6 cGy |
| Median values with range (minimum, maximum) in parentheses.

reported in Table 3. The beam-on time for delivery was below 6 min for all cases.

For single fraction plans, the patient-specific QA median pass rate was 99.0% (lowest of 96.2%), 97.0% (lowest of 91.8%), and 94.5% (lowest of 91.2%) when using a criterion of 3%/2 mm, 2%/2 mm, and 3%/1 mm respectively. For three fraction plans, the median pass rate was 97.5% (lowest of 94.2%), 95.4% (lowest of 90.7%), and 92.9% (lowest of 89.0%), respectively. For five fraction plans, the median pass rate was 97.8% (lowest of 95.8%), 94.9% (lowest of 90.7%), and 93.7% (lowest of 88.1%), respectively.

**4 | DISCUSSION**

Our results demonstrate that it is feasible to establish an automatic workflow to create high-quality treatment plans for spine SRS. The tool presented in this study automated plan creation, optimization, and calculation with the primary goal of meeting all OARs constraints while maximizing target coverage irrespective of lesion...
location, size, distance, and fractionation. Target coverage varied depending on the need to spare the most critical OARs, such as spinal cord, cauda equina, esophagus, trachea, and brachial plexus that, for some cases, are located adjacent to spinal metastases or even overlap with the PTV. As expected, the target coverage increased when the fractionation was increased due to the increased percent of the prescription dose allowed to be delivered to each OAR. The ability to create different fractionation plans provides an excellent tool to balance target coverage with the most optimal fractionation scheme.

All the plans presented here were obtained with only one optimization iteration, including one intermediate dose calculation, and without additional manual input in optimization. This approach was chosen in order to explore the feasibility of full plan automation; however, there is no reason why this tool could not be used in conjunction with a final manual input or a multicriteria optimization tool (MCO). One scenario we could envision in the use of this tool is an initial automatic multiplan generation, and subsequently, a final manual iteration for the plan with the fractionation selected. The main goals accomplished in our study rely on eliminating the time and effort required for plan creation, beam setup, optimization structure creation, creating/loading the appropriate optimization objectives pertinent to the lesion location on the spine, and setup optimization and calculation for multiple plans. In addition, due to the automatic nature of the process the time for creation of a large number of optimization structures that can be especially time consuming manually, becomes negligible. This is one of the script’s main features in order to force the steep gradient from the spinal cord limiting dose as effectively as possible while approaching the targets. The code is set up to evaluate the distance between dose limiting OARs and the target. Based on that distance and the dose objectives, a different number of optimization structures are created for each plan with the goal of maintaining the OARs constraint while also establishing an approximate 2 Gy per mm gradient to optimize target coverage. Therefore, the creation of optimization structures can be considered a customized process (not the same for every

Fig. 2. Axial view for three SRS treatment plans. Left: Single fraction plans [1800 cGy to gross tumor volume (GTV), 1600 cGy to planning target volume (PTV)]. Right: Three fraction plans (2700 cGy to GTV, 2100 cGy to PTV). Top: Thoracic spine case. Middle: Cervical spine case. Bottom: Lumbar spine case. GTV as red segment. PTV as pink segment. Spinal cord, brachial plexus, and cauda equine as blue contours. Esophagus as green contour.
FIG. 3. Dose volume histogram (DVH) for a thoracic spine case (T10). DVH includes gross tumor volume (GTV) (red dashed), clinical target volume (orange dashed), planning target volume (PTV) (pink dashed), spinal cord (blue), spinal cord + 2mm (dark blue), esophagus (green), heart (orange), and liver (brown). Top: Single-fraction plan (SIB 1800/1600 cGy to GTV/PTV). Middle: Three fractions plan (SIB 2700/2100 cGy to GTV/PTV). Bottom: Five fractions plan (3000 cGy to the PTV).
Automatic treatment planning for spine SRS/SBRT using scripting can facilitate the task of planning for spine metastases. Automatic planning through scripting increases efficiency, standardizes plan quality and approach, and provides a tool for target coverage comparison of different fractionation schemes without the need for additional resources.

5 CONFLICTS OF INTEREST

Honorarium from Varian Medical Systems (Jose Teruel) not directly related to the content of this manuscript.

REFERENCES

1. Bauerle T, Semmler W. Imaging response to systemic therapy for bone metastases. Eur Radiol. 2009;19:2495–2507.
2. Pinter NK, Pfiffner TJ, Mechtler LL. Neuroimaging of spine tumors. Handb Clin Neurol. 2016;136:689–706.
3. Delank KS, Wendtner C, Eich HT, Eysel P. The treatment of spinal metastases. Dtsch Arztebl. 2011;108:71–80.
4. Robin AM, Yamada Y, McLoughlin LA, et al. Stereotactic radiosurgery: the revolutionary advance in the treatment of spine metastases. Neurosurgery. 2017;64:59–65.
5. Ryu S, James J, Gerszten P, et al. RTOG 0631 phase II/III study of image-guided stereotactic radiosurgery for localized spine metastases: phase II results. Int J Radiat Oncol Biol Phys. 2011;81:S131–S132.
6. Zeng KL, Tseng CL, Soliman H, Weiss Y, Sahgal A, Myrehaug S. Stereotactic body radiotherapy (SBRT) for oligometastatic spine metastases: an overview. Front Oncol. 2019;9:337
7. Bishop AJ, Tao R, Rebueno NC, et al. Outcomes for spine stereotactic body radiation therapy and an analysis of predictors of local recurrence. Int J Radiat Oncol Biol Phys. 2015;92:1016–1026.
8. Tseng CL, Soliman H, Myrehaug S, et al. Imaging-based outcomes for 24 Gy in 2 daily fractions for patients with de novo spinal metastases treated with spine stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys. 2018;102:499–507.
9. Anand AK, Venkadamanickam G, Punnakal AJ, et al. Hypofractionated stereotactic body radiotherapy in spinal metastasis - with or without epidural extension. Clin Oncol. 2015;27:345–352.
10. Samaan M, Mantel F, Gerszten PC, et al. Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis. Radiat Oncol. 2014;9:226.
11. Thibault I, Al-Omair A, Masucci GL, et al. Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture. J Neurosurg. 2014;21:711–718.
12. Wang XS, Rhines LD, Shiu AS, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1–2 trial. Lancet Oncol. 2012;13:395–402.
13. Yamada Y, Bilsky MH, Lovelock DM, et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys. 2008;71:484–490.
14. Kockenberger M, Mantel F, Gerszten PC, et al. Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis. Radiat Oncol. 2014;9:226.
15. Thibault I, Al-Omair A, Masucci GL, et al. Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture. J Neurosurg. 2014;21:711–718.
16. Wang XS, Rhines LD, Shiu AS, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1–2 trial. Lancet Oncol. 2012;13:395–402.
17. Yamada Y, Bilsky MH, Lovelock DM, et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys. 2008;71:484–490.
18. Raman A, Verma S, Förster R, et al. Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy. Radiat Oncol. 2018;12:274–282.
19. Palma DA, Olson R, Harnow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051–2058.
20. Hall WA, Stapleford LJ, Hadjipanayis CG, Curran WJ, Crocker I, Shu H-KG. Stereotactic body radiosurgery for spinal metastatic disease: an evidence-based review. Int J Surg Oncol. 2011;2011:1–9.
21. Hsu M, Sahgal A, Pyror D, Redmond K, Lo S, Foote M. Stereotactic spine radiosurgery: review of safety and efficacy with respect to dose and fractionation. Surg Neurol Int. 2017;8:30.
22. Amdour RJ, Bennett J, Olivier K, et al. A prospective, phase II study demonstrating the potential value and limitation of radiosurgery for spine metastases. Am J Clin Oncol. 2009;32:515–520.
23. Gag AK, Shiu AS, Yang J, et al. Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases. Cancer. 2012;118:5069–5077.
24. Germano IM, Carai A, Pawha P, Blacksburg S, Lo Y-C, Green S. Clinical outcome of vertebral compression fracture after single fraction spine radiosurgery for spinal metastases. Clin Exp Metastasis. 2016;33:143–149.
25. Rose PS, Lauffer I, Boland PJ, et al. Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J Clin Oncol. 2009;27:5075–5079.
26. Moussazadeh N, Lis E, Katsoulakis E, et al. Five-year outcomes of high-dose single-fraction spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2015;93:361–367.
27. Cox BW, Spratt DE, Lovelock M, et al. International spine radiosurgery consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2012;83:e597–e605.
28. Gomez DR, Hunt MA, Jackson A, et al. Low rate of thoracic toxicity in palliative paraspinal single-fraction stereotactic body radiation therapy. Radiother Oncol. 2009;93:414–418.
29. Osborn VW, Lee A, Yamada Y. Stereotactic body radiation therapy for spinal malignancies. Technol Cancer Res Treat. 2018;17:153303381880230.
30. Cox BW, Jackson A, Hunt M, Blisky M, Yamada Y. Esophageal toxicity from high-dose, single-fraction paraspinal stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83:e661–e667.
31. Ayala GB, Doan KA, Ko HJ, et al. IMRT planning parameter optimization for spine stereotactic radiosurgery. Med Dosim. 2019;44:303–308.
32. Snyder KC, Wen N, Huang Y, et al. Use of jaw tracking in intensity modulated and volumetric modulated arc radiation therapy for spine stereotactic radiosurgery. Pract Radiat Oncol. 2015;5:e155–e162.
33. Zach L, Tsang L, Aleaza D, Ben Ayun M, Harel R. Volumetric modulated arc therapy for spine radiosurgery: superior treatment planning and delivery compared to static beam intensity modulated radiotherapy. Biomed Res Int. 2016;2016:1–6.
34. Mostakas C, Chan MKH, Kim J, et al. Treatment planning for spinal radiosurgery: a competitive multiplatform benchmark challenge. Strahlenther Onkol. 2018;194:843–854.
35. Raen DL, Crownover R, Stathakis S, Papanikolaou N. A dosimetric analysis of a spine SBRT specific treatment planning system. Appl Clin Med Phys. 2019;20:154–159.
36. Husain ZA, Sahgal A, De Salles A, et al. Stereotactic body radiotherapy for de novo spinal metastases: systematic review. J Neurosurg Spine. 2017;27:295–302.
37. Hassel I, Bzdusek K, Kumar P, et al. Automatic planning of head and neck treatment plans. J Appl Clin Med Phys. 2016;17:272–282.
38. Amit G, Purdie TG. Automated planning of breast radiotherapy using cone beam CT imaging. Med Phys. 2015;42:770–779.
39. Purdie TG, Dinniwel RE, Letourneau D, Hill C, Sharpe MB. Automated planning of tangential breast intensity-modulated radiotherapy using heuristic optimization. Int J Radiat Oncol Biol Phys. 2011;81:575–583.
40. Hussein M, Heijmen BJM, Verellen D, Nisbet A. Automation in intensity modulated radiotherapy treatment planning— a review of recent innovations. Br J Radiol. 2018;91:20180270.
41. Kunzel LA, Leibfarth S, Dohm OS, Muller A-C, Zips D, Thorwarth D. Automatic VMAT planning for post-operative prostate cancer cases using particle swarm optimization: a proof of concept study. Phys Med. 2020;69:101–109.
42. Marrazzo L, Arilli C, Pellegrini R, et al. Automated planning through robust templates and multicriterial optimization for lung VMAT SBRT of lung lesions. J Appl Clin Med Phys. 2020;21:114–120.
43. Foy JJ, Marsh R, Ten Haken RK, et al. An analysis of knowledge-based planning for stereotactic body radiation therapy of the spine. Pract Radiat Oncol. 2017;7:e355–e360.
44. Redmond KJ, Robertson S, Lo SS, Soltys SG, Roy S, McNutt T. Consensus contouring guidelines for postoperative stereotactic body radiation therapy for metastatic solid tumor malignancies to the spine. Int J Radiat Oncol Biol Phys. 2017;97:64–74.
45. Boyle-Fappiano D, Gyoshi O, Pezzi TA, et al. Spine stereotactic radiosurgery for metastatic thyroid cancer: a single-institution experience. J Neurosurg Spine. 2020;105:1–9.
46. Ghia AJ, Chang EL, Bishop AJ, et al. Single-fraction versus multifraction spinal stereotactic radiosurgery for spinal metastases from renal cell carcinoma: secondary analysis of phase II trials. J Neurosurg Spine. 2016;24:829–836.
43. Folkert MR, Bilsky MH, Tom AK, et al. Outcomes and toxicity for hypofractionated and single-fraction image-guided stereotactic radiosurgery for sarcomas metastasizing to the spine. *Int J Radiat Oncol Biol Phys*. 2014;88:1085–1091.

44. Grimm J, Sahgal A, Soltys SG, et al. Estimated risk level of unified stereotactic body radiation therapy dose tolerance limits for spinal cord. *Semin Radiat Oncol*. 2016;26:165–171.

45. Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. *Med Phys*. 2010;37:4078–4101.

46. Jain AK, Yamada YJ. The role of stereotactic body radiotherapy and stereotactic radiosurgery in the re-irradiation of metastatic spinal tumors. *Expert Rev Anticancer Ther*. 2014;14:1141–1152.